Global Cardiac Marker Testing

Cardiac Marker Testing Comprehensive Study by Type (Troponin I and T, CK-MB, Myoglobin, Brain Natriuretic Peptide (BNP), C - reactive protein (hsCRP), Other), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Laboratory Testing, Point-of-care Testing) Players and Region - Global Market Outlook to 2026

Cardiac Marker Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cardiac Marker Testing Market?

Cardiac marker testing is used to evaluate heart functions. It is used in the treatment of myocardial infarction and congestive heart failure by laboratory and point-of-care testing techniques. Cardiac marker testing market has high growth prospects owing to growing healthcare infrastructure in the developing economies, clinical trials for cardiac biomarkers. Further, the increasing number of patients with cardiovascular diseases driving the demand for cardiac market testing. For instance, according to the World Health Organization (WHO) 2018 report, cardiovascular diseases accounted for nearly 836,546 deaths in the United States that’s about 1 of every 3 deaths.

The market study is being classified by Type (Troponin I and T, CK-MB, Myoglobin, Brain Natriuretic Peptide (BNP), C - reactive protein (hsCRP) and Other) and major geographies with country level break-up.

Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (United States), Siemens AG (Germany), Danaher Corporation (United States), Alere, Inc. (United States), BioMérieux SA (France), Randox laboratories Ltd (United Kingdom), Guangzhou Wondfo Biotech Co., Ltd. (China), Bio-Rad Laboratories, Inc. (United States), Becton (United States) and Dickinson and Company (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Avantra Biosciences (United States), Helomics Corporation (United States) and Enzo Biochem (United States).

Leading global players are focusing on strategic partnerships to improve their products and services. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cardiac Marker Testing market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Cardiac Marker Testing market by Type, Application and Region.

On the basis of geography, the market of Cardiac Marker Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Cardiovascular Diseases
  • Growth in Geriatric Population

Market Trend
  • Increasing Application of Point-Of-Care Testing Technique
  • Emphasizing On Development of Novel Cardiac Biomarkers

Restraints
  • Stringent Government Regulations Regarding Cardiac Marker Testing

Opportunities
  • Emphasizing On Clinical Trials for Cardiac Biomarkers
  • Growing Healthcare Infrastructure in the Developing Economies

Challenges
  • Technical Complications Such As Collection and Storage of Sample





Key Target Audience
Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors, Contract Research Organizations (CROs), Diagnostic Kit Manufacturing Companies, Imaging Instrument Providers, Market Research and Consulting Firms, Pharmaceutical Companies and Others

Report Objectives / Segmentation Covered

By Type
  • Troponin I and T
  • CK-MB
  • Myoglobin
  • Brain Natriuretic Peptide (BNP)
  • C - reactive protein (hsCRP)
  • Other
By Disease
  • Myocardial Infarction
  • Congestive Heart Failure

By Testing
  • Laboratory Testing
  • Point-of-care Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Diseases
      • 3.2.2. Growth in Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Technical Complications Such As Collection and Storage of Sample
    • 3.4. Market Trends
      • 3.4.1. Increasing Application of Point-Of-Care Testing Technique
      • 3.4.2. Emphasizing On Development of Novel Cardiac Biomarkers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cardiac Marker Testing, by Type, Disease, Testing and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cardiac Marker Testing (Value)
      • 5.2.1. Global Cardiac Marker Testing by: Type (Value)
        • 5.2.1.1. Troponin I and T
        • 5.2.1.2. CK-MB
        • 5.2.1.3. Myoglobin
        • 5.2.1.4. Brain Natriuretic Peptide (BNP)
        • 5.2.1.5. C - reactive protein (hsCRP)
        • 5.2.1.6. Other
      • 5.2.2. Global Cardiac Marker Testing by: Disease (Value)
        • 5.2.2.1. Myocardial Infarction
        • 5.2.2.2. Congestive Heart Failure
      • 5.2.3. Global Cardiac Marker Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Cardiac Marker Testing (Price)
      • 5.3.1. Global Cardiac Marker Testing by: Type (Price)
  • 6. Cardiac Marker Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Diagnostics Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alere, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioMérieux SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Randox laboratories Ltd (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Guangzhou Wondfo Biotech Co., Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Becton (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Dickinson and Company (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cardiac Marker Testing Sale, by Type, Disease, Testing and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cardiac Marker Testing (Value)
      • 7.2.1. Global Cardiac Marker Testing by: Type (Value)
        • 7.2.1.1. Troponin I and T
        • 7.2.1.2. CK-MB
        • 7.2.1.3. Myoglobin
        • 7.2.1.4. Brain Natriuretic Peptide (BNP)
        • 7.2.1.5. C - reactive protein (hsCRP)
        • 7.2.1.6. Other
      • 7.2.2. Global Cardiac Marker Testing by: Disease (Value)
        • 7.2.2.1. Myocardial Infarction
        • 7.2.2.2. Congestive Heart Failure
      • 7.2.3. Global Cardiac Marker Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Cardiac Marker Testing (Price)
      • 7.3.1. Global Cardiac Marker Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cardiac Marker Testing: by Type(USD Million)
  • Table 2. Cardiac Marker Testing Troponin I and T , by Region USD Million (2015-2020)
  • Table 3. Cardiac Marker Testing CK-MB , by Region USD Million (2015-2020)
  • Table 4. Cardiac Marker Testing Myoglobin , by Region USD Million (2015-2020)
  • Table 5. Cardiac Marker Testing Brain Natriuretic Peptide (BNP) , by Region USD Million (2015-2020)
  • Table 6. Cardiac Marker Testing C - reactive protein (hsCRP) , by Region USD Million (2015-2020)
  • Table 7. Cardiac Marker Testing Other , by Region USD Million (2015-2020)
  • Table 8. Cardiac Marker Testing: by Disease(USD Million)
  • Table 9. Cardiac Marker Testing Myocardial Infarction , by Region USD Million (2015-2020)
  • Table 10. Cardiac Marker Testing Congestive Heart Failure , by Region USD Million (2015-2020)
  • Table 11. South America Cardiac Marker Testing, by Country USD Million (2015-2020)
  • Table 12. South America Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 13. South America Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 14. South America Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 15. Brazil Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 16. Brazil Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 17. Brazil Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 18. Argentina Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 19. Argentina Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 20. Argentina Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 21. Rest of South America Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 23. Rest of South America Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 24. Asia Pacific Cardiac Marker Testing, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 27. Asia Pacific Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 28. China Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 29. China Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 30. China Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 31. Japan Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 32. Japan Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 33. Japan Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 34. India Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 35. India Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 36. India Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 37. South Korea Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 38. South Korea Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 39. South Korea Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 40. Taiwan Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 41. Taiwan Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 42. Taiwan Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 43. Australia Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 44. Australia Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 45. Australia Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 49. Europe Cardiac Marker Testing, by Country USD Million (2015-2020)
  • Table 50. Europe Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 51. Europe Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 52. Europe Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 53. Germany Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 54. Germany Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 55. Germany Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 56. France Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 57. France Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 58. France Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 59. Italy Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 60. Italy Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 61. Italy Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 62. United Kingdom Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 64. United Kingdom Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 65. Netherlands Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 66. Netherlands Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 67. Netherlands Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 68. Rest of Europe Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 70. Rest of Europe Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 71. MEA Cardiac Marker Testing, by Country USD Million (2015-2020)
  • Table 72. MEA Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 73. MEA Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 74. MEA Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 75. Middle East Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 76. Middle East Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 77. Middle East Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 78. Africa Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 79. Africa Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 80. Africa Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 81. North America Cardiac Marker Testing, by Country USD Million (2015-2020)
  • Table 82. North America Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 83. North America Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 84. North America Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 85. United States Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 86. United States Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 87. United States Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 88. Canada Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 89. Canada Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 90. Canada Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 91. Mexico Cardiac Marker Testing, by Type USD Million (2015-2020)
  • Table 92. Mexico Cardiac Marker Testing, by Disease USD Million (2015-2020)
  • Table 93. Mexico Cardiac Marker Testing, by Testing USD Million (2015-2020)
  • Table 94. Cardiac Marker Testing: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Cardiac Marker Testing: by Type(USD Million)
  • Table 107. Cardiac Marker Testing Troponin I and T , by Region USD Million (2021-2026)
  • Table 108. Cardiac Marker Testing CK-MB , by Region USD Million (2021-2026)
  • Table 109. Cardiac Marker Testing Myoglobin , by Region USD Million (2021-2026)
  • Table 110. Cardiac Marker Testing Brain Natriuretic Peptide (BNP) , by Region USD Million (2021-2026)
  • Table 111. Cardiac Marker Testing C - reactive protein (hsCRP) , by Region USD Million (2021-2026)
  • Table 112. Cardiac Marker Testing Other , by Region USD Million (2021-2026)
  • Table 113. Cardiac Marker Testing: by Disease(USD Million)
  • Table 114. Cardiac Marker Testing Myocardial Infarction , by Region USD Million (2021-2026)
  • Table 115. Cardiac Marker Testing Congestive Heart Failure , by Region USD Million (2021-2026)
  • Table 116. South America Cardiac Marker Testing, by Country USD Million (2021-2026)
  • Table 117. South America Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 118. South America Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 119. South America Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 120. Brazil Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 121. Brazil Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 122. Brazil Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 123. Argentina Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 124. Argentina Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 125. Argentina Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 126. Rest of South America Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 127. Rest of South America Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 128. Rest of South America Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 129. Asia Pacific Cardiac Marker Testing, by Country USD Million (2021-2026)
  • Table 130. Asia Pacific Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 131. Asia Pacific Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 132. Asia Pacific Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 133. China Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 134. China Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 135. China Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 136. Japan Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 137. Japan Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 138. Japan Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 139. India Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 140. India Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 141. India Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 142. South Korea Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 143. South Korea Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 144. South Korea Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 145. Taiwan Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 146. Taiwan Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 147. Taiwan Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 148. Australia Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 149. Australia Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 150. Australia Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 154. Europe Cardiac Marker Testing, by Country USD Million (2021-2026)
  • Table 155. Europe Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 156. Europe Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 157. Europe Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 158. Germany Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 159. Germany Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 160. Germany Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 161. France Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 162. France Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 163. France Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 164. Italy Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 165. Italy Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 166. Italy Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 167. United Kingdom Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 168. United Kingdom Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 169. United Kingdom Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 170. Netherlands Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 171. Netherlands Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 172. Netherlands Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 173. Rest of Europe Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 174. Rest of Europe Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 175. Rest of Europe Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 176. MEA Cardiac Marker Testing, by Country USD Million (2021-2026)
  • Table 177. MEA Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 178. MEA Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 179. MEA Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 180. Middle East Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 181. Middle East Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 182. Middle East Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 183. Africa Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 184. Africa Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 185. Africa Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 186. North America Cardiac Marker Testing, by Country USD Million (2021-2026)
  • Table 187. North America Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 188. North America Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 189. North America Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 190. United States Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 191. United States Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 192. United States Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 193. Canada Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 194. Canada Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 195. Canada Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 196. Mexico Cardiac Marker Testing, by Type USD Million (2021-2026)
  • Table 197. Mexico Cardiac Marker Testing, by Disease USD Million (2021-2026)
  • Table 198. Mexico Cardiac Marker Testing, by Testing USD Million (2021-2026)
  • Table 199. Cardiac Marker Testing: by Type(USD/Units)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cardiac Marker Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Cardiac Marker Testing: by Disease USD Million (2015-2020)
  • Figure 6. South America Cardiac Marker Testing Share (%), by Country
  • Figure 7. Asia Pacific Cardiac Marker Testing Share (%), by Country
  • Figure 8. Europe Cardiac Marker Testing Share (%), by Country
  • Figure 9. MEA Cardiac Marker Testing Share (%), by Country
  • Figure 10. North America Cardiac Marker Testing Share (%), by Country
  • Figure 11. Global Cardiac Marker Testing: by Type USD/Units (2015-2020)
  • Figure 12. Global Cardiac Marker Testing share by Players 2020 (%)
  • Figure 13. Global Cardiac Marker Testing share by Players (Top 3) 2020(%)
  • Figure 14. Global Cardiac Marker Testing share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche Diagnostics Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche Diagnostics Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 20. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens AG (Germany) Revenue: by Geography 2020
  • Figure 22. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Danaher Corporation (United States) Revenue: by Geography 2020
  • Figure 24. Alere, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Alere, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. BioMérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 27. BioMérieux SA (France) Revenue: by Geography 2020
  • Figure 28. Randox laboratories Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Randox laboratories Ltd (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Guangzhou Wondfo Biotech Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 31. Guangzhou Wondfo Biotech Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 32. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Becton (United States) Revenue, Net Income and Gross profit
  • Figure 35. Becton (United States) Revenue: by Geography 2020
  • Figure 36. Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 37. Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 38. Global Cardiac Marker Testing: by Type USD Million (2021-2026)
  • Figure 39. Global Cardiac Marker Testing: by Disease USD Million (2021-2026)
  • Figure 40. South America Cardiac Marker Testing Share (%), by Country
  • Figure 41. Asia Pacific Cardiac Marker Testing Share (%), by Country
  • Figure 42. Europe Cardiac Marker Testing Share (%), by Country
  • Figure 43. MEA Cardiac Marker Testing Share (%), by Country
  • Figure 44. North America Cardiac Marker Testing Share (%), by Country
  • Figure 45. Global Cardiac Marker Testing: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Roche Diagnostics Ltd. (Switzerland)
  • Abbott Laboratories (United States)
  • Siemens AG (Germany)
  • Danaher Corporation (United States)
  • Alere, Inc. (United States)
  • BioMérieux SA (France)
  • Randox laboratories Ltd (United Kingdom)
  • Guangzhou Wondfo Biotech Co., Ltd. (China)
  • Bio-Rad Laboratories, Inc. (United States)
  • Becton (United States)
  • Dickinson and Company (United States)
Additional players considered in the study are as follows:
Avantra Biosciences (United States) , Helomics Corporation (United States) , Enzo Biochem (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 153 Pages 55 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cardiac Marker Testing Quantitative research analysis
Global Cardiac Marker Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Prevalence of Cardiovascular Diseases " is seen as one of major growth factors of Cardiac Marker Testing Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Cardiac Marker Testing Market in coming years.

Know More About Global Cardiac Marker Testing Report?

Have a Query? Click Here

Other Related Reports

Solid Phase Extraction Apparatus Comprehensive Study by Application (Pharma, Academia, Hospital & Clinical, Environmental), Volume (Small Volume, Large Volume), Material (Water, Serum, Urine, Milk, P...
$ 3450
Trauma Implants Comprehensive Study by Type (Metal plates & Screws, Pins/Wires, Nails & Rods, Others), Type (Internal, External Fixators), End-Use Industries (Hospitals, Orthopedic Clinics, Ambulato...
$ 3350
Capillary Electrophoresis Comprehensive Study by Type (Capillary Zone Electrophoresis (CZE), Capillary Gel Electrophoresis (CGE), Capillary Electro Chromatography (CEC), Others), Application (Versati...
$ 3750
In situ Hybridization Comprehensive Study by Application (Cancer Diagnosis, Immunology, Neuroscience, Cytology, Infectious Diseases), Technique (Fluorescence In Situ Hybridization (FISH) (DNA-FISH, R...
$ 3750
Healthcare Chatbots Comprehensive Study by Application (Symptom Check, Medical Assistance, Appointment Booking), End User (Patient, Healthcare Providers, Insurance Companies), Component (Software, S...
$ 3350
Atomic Spectroscopy Comprehensive Study by Application (Pharmaceuticals & Biotechnology, Geochemical/Mining, Industrial Chemistry, Environmental Testing, Food & Beverage Testing, Petrochemical, Other...
$ 3750